Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
02:56pm, Tuesday, 12'th Mar 2024
Incyte's (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.
The Stock Market Is Already Way Up. 8 Stocks That Can Still Outperform.
01:42pm, Monday, 11'th Mar 2024
Finding promising stocks is harder, given that the S&P 500 has risen by about one-third over 12 months.
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
01:02pm, Monday, 11'th Mar 2024
The allure of penny stocks is understandable. For literally just a few dollars, you can control hundreds, if not thousands, of shares.
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
03:00pm, Thursday, 07'th Mar 2024
The global oncology ecosystem is at a pivotal juncture. Significant advancements in discovery, development, and delivery of novel cancer treatments are enhancing patient outcomes.
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
03:20pm, Monday, 26'th Feb 2024
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
Exit Now! 3 Biotech Stocks to Sell in February 2024
04:50pm, Wednesday, 21'st Feb 2024
The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biote
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
12:41pm, Tuesday, 13'th Feb 2024
Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opz
Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript
12:37pm, Tuesday, 13'th Feb 2024
Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript
Here's What Key Metrics Tell Us About Incyte (INCY) Q4 Earnings
10:36am, Tuesday, 13'th Feb 2024
The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Incyte (INCY) Lags Q4 Earnings and Revenue Estimates
09:26am, Tuesday, 13'th Feb 2024
Incyte (INCY) came out with quarterly earnings of $1.06 per share, missing the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $0.62 per share a year ago.
Ahead of Incyte (INCY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:21am, Friday, 09'th Feb 2024
Evaluate the expected performance of Incyte (INCY) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
Incyte (INCY) Banks on Opzelura as Jakafi Faces Competition
10:16am, Friday, 26'th Jan 2024
Incyte (INCY) is likely to rebound in 2024 on the solid growth of Opzelura and additional label expansions.
5 top healthcare stocks for earnings growth in 2024
07:09am, Thursday, 25'th Jan 2024
Sector components forecast to show the biggest earnings year-over-year earnings improvement include Humana Inc. NYSE: HUM, Elevance Health Inc. NYSE: ELV, Incyte Corp. NASDAQ: INCY, Insulet Corp.
Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024
09:13am, Tuesday, 09'th Jan 2024
Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.
5 Biotech Acquisition Targets To Accumulate In 2024
01:05pm, Thursday, 21'st Dec 2023
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid
